scanX
Home
Glenmark Pharmaceuticals

Glenmark Pharmaceuticals

1,406.40
+31.40
(2.28%)
search
Market Cap
39,686.94 Cr
EPS
-53.22
PE Ratio
-
Dividend Yield
0.18 %
Industry
Healthcare
52 Week High
1,830.95
52 Week Low
985.20
PB Ratio
4.60
Debt to Equity
0.34
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from9 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+66.67 %
+66.67 %
Hold
Hold+22.22 %
+22.22 %
Sell
Sell+11.11 %
+11.11 %

Company News

View All News
Caret
positive
Glenmark Pharmaceuticals: FDA Grants Fast Track Status to Multiple Myeloma Drug8 hours ago
Glenmark's subsidiary, Ichnos Glenmark Innovation, received FDA fast track designation for ISB 2001, a tri-specific antibody therapeutic for relapsed or refractory multiple myeloma. The drug showed promising results in phase 1 trials, with complete results to be presented at the 2025 ASCO annual meeting. ISB 2001 previously received orphan drug designation in July 2023.
positive
Glenmark's Subsidiary Receives FDA Fast Track Designation for Multiple Myeloma Treatment9 hours ago
Ichnos Glenmark Innovation (IGI), a subsidiary of Glenmark Pharma, has been granted Fast Track Designation by the U.S. FDA for ISB 2001, a potential treatment for relapsed/refractory multiple myeloma. This designation is expected to expedite the development and review process of the drug.
neutral
Glenmark Pharma Clarifies Report on Spurious Drugs5 days ago
Glenmark Pharmaceuticals has issued a clarification regarding a report about the Central Drugs Standard Control Organisation (CDSCO) flagging certain drugs. The company states that the products mentioned in the report are spurious and were not manufactured by Glenmark. This clarification aims to address potential concerns about the quality and authenticity of Glenmark's pharmaceutical products.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,836.60
#1 4,40,661.86
37.20
#1 49,887.20
12.06
#1 9,648
13.77
62.24
Divis Laboratories
6,124.50
1,62,586.23
78.35
8,184.00
0.89
1,600
#1 64.53
60.86
Cipla
1,542.90
1,24,606.91
24.70
26,520.70
14.17
4,155
47.38
57.59
Torrent Pharmaceuticals
3,285.20
1,11,186.10
59.18
10,785.70
11.59
1,656
13.54
54.31
Mankind Pharma
2,415.40
99,654.22
48.14
10,615.60
19.57
1,942
-16.38
46.37
Dr Reddys Laboratories
1,171.30
97,739.76
#1 18.38
28,905.40
12.36
5,578
1.69
51.52
Lupin
2,085.30
95,202.48
32.75
20,141.50
#1 19.94
1,936
38.82
54.25
Zydus Life Science
892.50
89,806.38
19.65
19,831.50
13.82
3,831
29.92
53.95
Aurobindo Pharma
1,242.00
72,135.56
19.97
29,559.20
17.55
3,169
-10.04
59.05
Abbott
30,725.00
65,288.48
48.97
6,097.20
10.80
1,201
16.01
55.94
Growth Rate
Revenue Growth
6.58 %
Net Income Growth
1,943.30 %
Cash Flow Change
-142.44 %
ROE
2,463.74 %
ROCE
56.66 %
EBITDA Margin (Avg.)
-0.74 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
1,754
1,631
1,880
1,749
2,211
1,986
2,171
2,478
2,373
2,345
2,253
2,148
2,317
2,268
2,847
2,401
2,565
2,285
2,845
2,672
2,788
2,396
2,879
2,787
2,838
3,005
3,112
3,155
3,068
2,903
3,069
3,272
3,062
3,018
3,281
2,625
3,814
3,255
3,440
3,333
Expenses
1,682
1,288
1,506
1,408
2,003
1,590
1,775
1,770
2,094
1,786
1,868
1,881
1,953
1,819
2,141
2,120
2,199
1,981
2,365
2,296
2,302
1,867
2,400
2,257
2,337
2,391
2,557
2,659
2,638
2,346
2,539
2,626
3,402
2,651
3,071
2,792
3,005
2,656
2,832
2,787
EBITDA
73
343
374
341
208
395
396
708
279
559
385
267
365
449
706
280
366
304
480
376
487
529
480
531
502
614
555
497
430
558
530
646
-340
367
211
-168
808
599
608
546
Operating Profit %
4 %
21 %
20 %
19 %
9 %
17 %
18 %
28 %
14 %
23 %
16 %
13 %
13 %
15 %
16 %
16 %
13 %
13 %
14 %
13 %
15 %
19 %
17 %
18 %
17 %
19 %
18 %
15 %
11 %
14 %
15 %
14 %
-15 %
12 %
3 %
-13 %
0 %
18 %
17 %
16 %
Depreciation
65
65
59
52
58
64
69
63
69
78
75
75
74
79
82
83
81
91
94
106
126
113
104
115
111
113
123
119
132
147
146
152
135
142
141
147
151
118
120
123
Interest
40
42
43
47
48
43
63
62
70
71
70
71
74
79
85
89
82
93
90
96
99
94
81
95
83
76
69
67
87
60
83
97
109
112
122
134
149
40
49
52
Profit Before Tax
-10
257
303
274
209
348
315
655
173
444
273
154
249
327
580
154
240
160
347
271
318
358
339
348
338
444
385
343
270
408
337
435
-542
151
-6
-403
555
462
473
456
Tax
-20
75
87
78
60
121
92
178
-11
111
59
49
97
94
166
38
79
51
92
80
98
104
105
100
104
137
110
103
97
197
58
144
-139
-22
56
-72
1,770
122
118
108
Net Profit
11
183
216
196
149
227
224
477
184
333
214
105
152
233
414
116
162
109
256
191
220
254
234
248
234
307
275
240
173
211
279
291
-403
173
-62
-331
-1,214
340
355
348
EPS in ₹
0.39
6.66
7.66
6.95
5.28
8.04
7.92
16.91
6.51
11.81
7.59
3.71
5.37
8.26
14.67
4.12
5.73
3.87
9.06
6.76
7.81
9.00
8.29
8.80
8.29
10.86
9.13
7.86
5.51
6.82
9.23
9.66
-15.18
5.31
-2.90
-12.45
-43.17
12.06
12.55
12.33
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
9,688
10,193
11,764
12,595
13,296
14,685
15,604
17,083
19,372
14,359
Fixed Assets
2,836
2,594
2,755
3,030
3,670
5,029
5,129
5,887
5,422
4,210
Current Assets
5,323
5,904
6,875
6,989
6,697
6,804
7,360
8,282
10,726
7,428
Capital Work in Progress
492
543
708
1,122
1,399
1,222
1,382
1,010
1,190
662
Investments
0
17
16
15
30
25
25
50
45
790
Other Assets
6,359
7,039
8,285
8,429
8,197
8,410
9,068
10,137
12,716
8,697
Total Liabilities
9,688
10,193
11,764
12,595
13,296
14,685
15,604
17,083
19,372
14,359
Current Liabilities
3,711
3,999
2,703
3,288
4,021
4,126
4,201
4,689
5,105
5,819
Non Current Liabilities
2,976
2,564
4,569
4,144
3,670
4,489
4,338
2,956
4,427
693
Total Equity
3,000
3,629
4,492
5,163
5,605
6,070
7,064
9,438
9,839
7,848
Reserve & Surplus
2,973
3,601
4,464
5,135
5,577
6,042
7,036
9,058
9,446
7,820
Share Capital
27
28
28
28
28
28
28
28
28
28
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-31
93
199
177
-297
174
28
272
33
215
Investing Activities
-712
-950
-1,001
-1,003
-883
-774
-662
-316
-515
4,387
Operating Activities
482
345
657
1,648
1,324
1,392
1,131
1,109
625
-265
Financing Activities
199
699
543
-469
-739
-445
-442
-521
-78
-3,906
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
46.63 %
46.63 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.64 %
46.65 %
46.65 %
46.65 %
46.65 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
24.80 %
23.71 %
21.38 %
20.98 %
23.05 %
23.51 %
23.16 %
DIIs
3.82 %
4.94 %
5.09 %
7.08 %
6.62 %
6.01 %
10.64 %
10.69 %
10.41 %
9.11 %
10.32 %
10.92 %
13.36 %
13.92 %
13.21 %
13.85 %
14.60 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
Public / Retail
15.92 %
14.43 %
16.02 %
15.88 %
15.88 %
16.32 %
16.47 %
16.72 %
16.90 %
15.20 %
14.83 %
14.77 %
14.83 %
14.58 %
13.61 %
12.65 %
12.32 %
Others
33.63 %
34.00 %
32.25 %
30.40 %
30.86 %
31.02 %
26.21 %
25.91 %
26.01 %
29.01 %
3.37 %
3.92 %
3.75 %
3.83 %
3.45 %
3.31 %
3.24 %
No of Share Holders
2,50,849
2,75,801
3,29,870
3,17,383
3,10,516
3,12,473
3,13,540
3,00,106
2,85,461
2,36,908
2,32,685
2,09,931
1,99,451
1,92,630
1,93,949
1,95,059
1,92,724

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 2 2 2 2 2.5 2.5 2.5 2.5 2.5 0.00
Dividend Yield (%) 0.23 0.38 0.31 0.97 0.54 0.57 0.56 0.26 0.16 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 Feb 2025 1,436.30 1,411.20
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 14 Nov 2024 1,673.95 1,539.40
27 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 27 Sept 2024 1,684.85 1,676.95
17 Sept 2024 DIVIDEND Dividend
₹ 2.50 /share
 13 Sept 2024 1,027.60 1,741.85
29 Sept 2023 ANNUAL GENERAL MEETING Annual General Meeting
NA
 29 Sept 2023 749.15 776.95
19 Sept 2023 DIVIDEND Dividend
₹ 2.50 /share
 18 Sept 2023 604.10 850.75
14 Sept 2022 DIVIDEND Dividend
₹ 2.50 /share
 12 Sept 2022 397.90 393.35
10 Sept 2021 DIVIDEND Dividend
₹ 2.50 /share
 08 Sept 2021 606.70 524.55

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release10 hours ago
Rumour verification - Regulation 30(11)6 days ago
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B27 days ago
Clarification sought from Glenmark Pharmaceuticals Ltd7 days ago
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A7 days ago
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot10 days ago
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 17, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 16, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 27, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotMar 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 20, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 03, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 27, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015: Glenmark Pharmaceuticals Ltd. (Hereinafter Referred As The Company)Feb 24, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 17, 2025
Integrated Filing (Financial)Feb 14, 2025
U.S. FDA Inspection At The Companys Facility At Indore Madhya Pradesh IndiaFeb 14, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 14, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 14, 2025
Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended 31St December 2024Feb 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 10, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 08, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2025
Closure of Trading WindowFeb 03, 2025
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31 2024.Feb 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 21, 2025
Intimation Of Change In The Name Of The Step Down Wholly Owned Subsidiaries Of The Company.Jan 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 16, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 10, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 27, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 27, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 21, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 18, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationNov 14, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 14, 2024
Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended 30Th September, 2024Nov 14, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 06, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2024

Technical Indicators

RSI(14)
Neutral
49.42
ATR(14)
Less Volatile
49.33
STOCH(9,6)
Neutral
47.26
STOCH RSI(14)
Neutral
75.78
MACD(12,26)
Bearish
-0.37
ADX(14)
Weak Trend
23.45
UO(9)
Bearish
45.09
ROC(12)
Uptrend And Accelerating
2.14
WillR(14)
Neutral
-31.58
Bearish
4
Neutral
4
Bullish
1

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd is an Indian research-led global pharmaceutical company founded in 1977. It focuses on developing and manufacturing branded generics, generic drugs, and over-the-counter products in therapeutic areas like respiratory, dermatology, and oncology. The company has a significant presence in emerging markets and operates 14 manufacturing facilities across several countries. Glenmark is involved in drug discovery for new chemical and biological entities, with molecules in various stages of development. It has a strong generics business serving markets like the US and Europe, and an active pharmaceutical ingredients business selling to over 80 countries. The company has made several acquisitions and licensing deals to expand its product portfolio and global reach. Glenmark has launched numerous products across various therapeutic segments and markets, including innovative combinations and first-to-market generics. It has a substantial pipeline of ANDAs filed with the US FDA and continues to receive approvals for new generic products.
Website
https://www.glenmarkpharma.com
Chairperson NameGlenn Saldanha
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Price & Volume Screeners
Technical Screeners
Intraday Screeners
Fundamental Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Corporate Office: A-302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai – 400066, Maharashtra, India. Land Line: 022-43116666.